Avedro, Inc.
230 Third Avenue
Waltham
Massachusetts
02451
United States
Tel: 781-768-3400
Fax: 781-768-3401
Website: http://www.avedro.com/
70 articles about Avedro, Inc.
-
Glaukos Completes Acquisition of Avedro, Inc.
11/21/2019
Glaukos Corporation announced that it has completed its previously announced acquisition of Avedro, Inc.
-
AVEDRO, INC. SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces an Investigation of Avedro, Inc. (AVDR) Over the Proposed Merger of the Company with Glaukos Corporation
9/28/2019
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating the proposed merger of Avedro, Inc. with Glaukos Corporation.
-
Glaukos and Avedro Announce Definitive Acquisition Agreement
8/7/2019
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, and Avedro, Inc. (Nasdaq: AVDR), a leading hybrid ophthalmic pharmaceutical and medical technology company focused on treating corneal disease and disorders, today announced that the companies have entered into a definitive merger agreement
-
A summary of IPOs from companies in the biotech and pharma world since January 1, 2019.
-
Permanent J Code Issued for Avedro’s Photrexa® Drug Formulations
11/20/2018
J Code 2787, Effective January 1, 2019, Expected to Streamline Reimbursement and Expand Patient Access
-
Cigna Is Newest Payer to Join Growing List of Commercial Plans Covering Avedro’s FDA-Approved Cross-Linking Procedure—133 Million Lives Covered in Total
9/25/2018
Avedro Names Tim Homer Vice President of Health Policy & Market Access in Continued Effort to Expand Market Access and Reimbursement of Cross-Linking
-
Thomas W. Burns, CEO of Glaukos, Joins Avedro’s Board of Directors
7/31/2018
Avedro, Inc. today announced that Thomas W. Burns has been elected to its Board of Directors.
-
Avedro Announces Enrollment of First Patient in U.S. Pivotal Phase 3 Epi-on Corneal Cross-Linking Trial for Progressive Keratoconus
6/18/2018
Clinical Study to Support Application for FDA Approval for Epi-on Corneal Cross-Linking Procedure with New Drug Formulation and Use of Oxygen.
-
CMS Issues Preliminary Decision on Unique J Code for Avedro Photrexa® Drug Formulations
6/12/2018
Avedro, Inc. announced that the Centers for Medicare and Medicaid Services (CMS) has issued a preliminary decision to establish a product specific Healthcare Common Procedure Coding System (HCPCS) J code for Photrexa® drug formulations.
-
Avedro Announces $25 Million in Funding to Fuel Innovation and Commercial Growth
5/2/2018
Hongbo Lu, PhD, Joins Avedro Board of Directors
-
Avedro Names James Schuermann Chief Business Officer
4/10/2018
Mr. Schuermann will lead the global government affairs, health economics and reimbursement, communications, sales, field service, marketing and business development functions and will report to Avedro’s Chief Executive Officer, Reza Zadno.
-
Avedro Announces Agreement with the FDA for the First U.S. Pivotal Phase 3 Trial of an Epi-on Cross-Linking Treatment for Patients with Progressive Keratoconus
3/15/2018
Procedure Includes New Drug Formulation and Use of Oxygen
-
Avedro Marks the First Anniversary of Availability of the Only FDA Approved Corneal Cross-Linking Treatment in The U.S.
11/9/2017
Avedro, today marked the one year anniversary of the U.S. commercial availability of Photrexa Viscous and Photrexa.
-
Donald J. Zurbay Joins Avedro’s Board Of Directors
7/18/2017
-
Avedro Names Thomas E. Griffin Chief Financial Officer
6/20/2017
-
Massachusetts' Avedro Banks $42 Million, Opens New Facility and Will Continue to Expand Its Team
4/27/2017
-
Avedro Release: First US Service Members Treated With The Only FDA-Approved Cross-Linking Procedure In The U.S.
1/11/2017
-
Avedro Release: First FDA Approved Cross-Linking Procedures Are Performed On Patients In The U.S. With Progressive Keratoconus
9/28/2016
-
Avedro Release: Two Studies Demonstrate Promising Results Of PiXL Procedure (Photorefractive Intrastromal Corneal Collagen Cross-Linking) For Non-Invasive Treatment Of Low Myopia
9/12/2016
-
Avedro Appoints Dr. Reza Zadno as CEO
9/8/2016